GlassScriptPhysician profile
Kayla M Shackleton
NPI 1033725437
$9,235.70
in general payments reported to CMS, 2019-2025
29 companies · $2,605 in 2025
The $2,605 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,678 · 2022: $1,956 · 2023: $1,993 · 2024: $1,003 · 2025: $2,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,047 · Travel and Lodging: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,046.71 |
| Travel and Lodging | $554.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,030.23 | 2021-2025 | Cardiomems, Perclose Prostyle |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,455.26 | 2021-2025 | Lifevest |
| Medtronic, INC. | $1,118.63 | 2025 | Linq II, Micra, Mycarelink |
| Impulse Dynamics (USA) INC. | $580.44 | 2021-2025 | Optimizer, Optimizer |
| Abiomed | $561.47 | 2023-2025 | Impella |
| Amgen INC. | $360.20 | 2021-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $355.62 | 2024-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $349.02 | 2021-2022 | |
| Novo Nordisk INC | $326.46 | 2021-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $286.10 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $275.44 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $273.85 | 2021-2023 | Lux-Dx Insertable Cardiac Monitor |
| Inari Medical, INC. | $192.65 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biotronik INC. | $188.03 | 2025 | Biomonitor, Amvia Edge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.34 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $131.52 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $121.82 | 2023 | Opsumit, Uptravi |
| Biosense Webster, INC. | $104.33 | 2021 | |
| Cvrx, INC. | $89.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $64.99 | 2021-2022 | |
| Pfizer INC. | $48.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $39.04 | 2022-2025 | Farxiga |
| Nevro Corp. | $26.30 | 2023 | Senza |
| Atricure, INC. | $25.96 | 2022 | |
| Akcea Therapeutics, INC. | $23.13 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.21 | 2021 | |
| Cardiva Medical, INC. | $17.78 | 2021 | |
| Philips North America LLC | $16.59 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Shackleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.